ESH EUROPEAN SCHOOL OF HAEMATOLOGY

2nd HOW TO DIAGNOSE AND TREAT MULTIPLE MYELOMA

April 5-7, 2019 - Berlin, Germany

Chairs: Hermann Einsele, Irene Ghobrial, Sonja Zweegman

Friday, April 5th, 2019

Registration opens at 12:30 – (Sandwiches on site)

13.55 WELCOME ADDRESS: Hermann Einsele, Sonja Zweegman

SESSION I – BIOLOGY OF THE DISEASE – IMPACT ON THERAPY AND OUTCOME
Chairs: Hermann Einsele (Würzburg), Sonja Zweegman (Amsterdam)

Introduction:

14:00-14:15	Genetic basis and treatment of high-risk multiple myeloma	Gareth Morgan (New York)
14:15-14-20	*Discussion*	
14:20-14:35	High risk disease – from definition to treatment	Jonathan Keats (Phoenix)
14:35-14:40	*Discussion*	
14:40-14:55	What is old – from biology of the disease to patient	Sonja Zweegman (Amsterdam)
14:55-15:00	*Discussion*	
15:00-15:10	*Interactive discussion*	
15:10-15:30	Functional imaging characteristics of myeloma - promising now, predicting in the future?	Elena Zamagni (Bologna)
15:30-15:35	*Discussion*	

15:35-16:05 Coffee Break

16:05-16:55 **DEBATE I: BONE DISEASE**
Chair: Elena Zamagni (Bologna)

Audience votes “continuous treatment” or “personalized limited treatment”

16:05-16:25	Bone disease – continuous treatment	Charlotte Pawlyn (London)
16:25-16:30	*Discussion*	
16:30-16:50	Bone disease – personalized limited treatment	Evangelos Terpos (Athens)
16:50-16:55	*Discussion*	

Audience votes “continuous treatment” or “personalized limited treatment”

16:55-17:40 **INTERACTIVE CASES**
Chairs: Hermann Einsele (Würzburg), Sonja Zweegman (Amsterdam)

16:55-17:02 Efficacy of Daratumumab (DARA) plus standard of care (SoC) regimens in lenalidomide (len)-exposed or – refractory patients with relapsed/refractory multiple myeloma (RRMM): analysis of Castor, Pollux, and MMY1001 — Thierry Facon (Lille)
17:02-17:05 *Discussion*

17:05-17:12 Sustained minimal residual disease (MRD) negativity in relapsed/refractory multiple myeloma (RRMM) patients who received Daratumumab plus Lenalidomide and Dexamethasone (D-Rd) or Bortezomib and Dexamethasone (D-Vd): analysis of Pollux and Castor — Katja Weisel (Tübingen)
17:12-17:15 *Discussion*

17:15-17:22 Prognostic significance of the expression of tumor antigens CD56, CD 117, CD33, CD20 as prognostic factors in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma — Zhanna Kozich (Gomel)
17:22-17:25 *Discussion*

17:25-17:32 Multiple myeloma-derived exosomes promote skeletal colonization and disease progression — Ryan Bishop (Tampa)
17:32-17:35 *Discussion*

18:00-19:00 **SATELLITE SYMPOSIUM:**
Transplantation and CAR-T cell therapy in multiple myeloma : leveraging the immune system to optimize outcomes
Chair: Hermann Einsele (Würzburg)
Speakers: Hermann Einsele (Würzburg), Paula Rodriguez-Otero (Pamplona)

This symposium is organised and funded by Celgene

19:00 ***Get together and poster walks (stand up cocktails and buffet dinner for all)***

Saturday, April 6th, 2019

07:55-08:45 **Simultaneous Meet the Expert Sessions**

1. Stem cell transplantation — Francesca Gay (Turin)
2. Multiple myeloma imaging — Elena Zamagni (Bologna)
3. Multiple myeloma genomics — Gareth Morgan (New York)

SESSION II – TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA AND PLASMA CELL DYSCRASIA
Chairs: Hermann Einsele (Würzburg), Gareth Morgan (New York)

08:55-09:10 Transplant eligible — Michele Cavo (Bologna)
09:10-09:15 *Discussion*

09:15-09:30 Transplant non-eligible — Thierry Facon (Lille)
09:30-09:35 *Discussion*

09:35-09:45 *Interactive discussion*

09:45-10:05 Amyloidosis from diagnosis to treatment — Giovanni Palladini (Pavia)
10:05-10:10 *Discussion*

10:10-10:30 Monoclonal gammopathy of clinical significance — Angela Dispenzieri (Rochester)
10:30.10:35 *Discussion*

10:35-10:55 Waldenstrom Macroglobulinemia — Jorge J. Castillo (Boston)
10:55-11:00 *Discussion*

11:00-11:20 Coffee Break

SESSION III – TREATMENT OF REFRACTORY / RELAPSED MULTIPLE MYELOMA
Chairs: Francesca Gay (Turin), Sonja Zweegman (Amsterdam)

11:20-11:35 First relapse in transplant eligible — Sagar Lonial (Atlanta)
11:35-11:40 *Discussion*

11:40-12:05 First relapse in transplant non eligible — Karthik Ramasamy (Oxford)
12:05-12:10 *Discussion*

12:10-12:35 Late relapse — Stefan Knop (Würzburg)
12:35-12:40 *Discussion*

12:40-13:00 Panel discussion

13:00-13:10 **ESH International Scholarship Fund** — *Hermann Einsele (Würzburg)*
Early-Career Scholarship Award Ceremony — *Sonja Zweegman (Amsterdam)*

13:10-14:50 Lunch

13:40-14:40 **SATELLITE SYMPOSIUM:**
How I treat my multiple myeloma patients at diagnosis and first relapse :
A case study-based discussion
Chair: Hermann Einsele (Würzburg)
Speakers: Gordon Cook (Leeds), Niels van de Donk (Amsterdam)

Organised and supported by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA

14:50-15:40 **ROUNDTABLE I: HOT TOPICS IN MYELOMA THERAPY**
Chairs: Stefan Knop (Würzburg), Niels van de Donk (Amsterdam)

14:50-15:10 How to manage side effects — Inger Nijhof (Amsterdam)
15:10-15:15 *Discussion*

15:15-15:35 Smouldering disease – from definition to treatment — Salomon Manier (Lille)
15:35-15:40 *Discussion*

SESSION IV - FROM STUDIES TO REALITY
Chairs: Gordon Cook (Leeds), Sagar Lonial (Atlanta)

15:40-16:00	A transplant-eligible patient with an aggressive relapse 12 months after autologous stem cell transplant – what to do now?	Paula Rodriguez (Pamplona)
16:00-16:05	*Discussion*	
16:05-16:25	A transplant- ineligible patient with partial response after 12 cycles of lenalidomide-dexamethasone – to continue, to limit, to change?	Inger Nijhof (Amsterdam)
16:25-16:30	*Discussion*	
16:30-16:50	A transplant-eligible patient with a non-aggressive relapse 24 months after autologous stem cell transplant followed by lenalidomide maintenance	Francesca Gay (Turin)
16:50-16:55	*Discussion*	
16:55-17:15	A patient with proteasome inhibitors- and immunomodulatory drugs -refractory disease	Salomon Manier (Lille)
17:15-17:20	*Discussion*	
17:20-17:50	***Coffee break***	
17:50-18:10	Is this multiple myeloma? A patient with high serum light chains and renal failure.	Stefan Knop (Würzburg)
18:10-18:15	*Discussion*	

18:15-19:05 **ROUNDTABLE II: HOW TO DESIGN AND INTERPRET CLINICAL TRIALS IN MYELOMA**
Chairs: Hermann Einsele (Würzburg), Sonja Zweegman (Amsterdam)

18:15-18:35	What kind of trials do we need in the future to address open issues in NDMM? Better research, better impact	Gordon Cook (Leeds)
18:35-18:40	*Discussion*	
18:40-19:00	Meta-analyses – how to interpret and to translate to clinical practice	Robert Hills (Oxford)
19:00-19:05	*Discussion*	

FREE EVENING

Sunday, April 7th, 2019

08:00-08:50 **Simultaneous Meet the Expert Sessions**

1. Bone disease	Evangelos Terpos (Athens)
2. Immunotherapy	Niels van de Donk (Amsterdam)
3. CAR T-cells	Michael Hudecek (Würzburg), Sabrina Pommersberger (Würzburg)

SESSION V - THE FUTURE IS NOW
Chairs: Niels van de Donk (Amsterdam), Sonja Zweegman (Amsterdam)

Session kindly supported by Celgene.

09:00-09:20	Car-T cell basics	Michael Hudecek (Würzburg)
09:20-09:25	*Discussion*	
09:25-09:45	Car-T cell in clinical practice	Hermann Einsele (Würzburg)
09:45-09:50	*Discussion*	
09:50-10:10	Antibody based immune therapy	Niels Van De Donk (Amsterdam)
10:10-10:15	*Discussion*	
10:15-10:35	Bispecific antibodies in the treatment of multiple myeloma	Hermann Einsele (Würzburg)
10:35-10:40	*Discussion*	
10:40-11:00	*Panel discussion*	

11:00-11:30 Coffee Break

11:30-12:20 DEBATE II: USE HIGH CUT OFF FILTERS IN MULTIPLE MYELOMA WITH LIGHT CHAIN KIDNEY DISEASE
Chairs: Stefan Knop (Würzburg), Khartik Ramasamy (Oxford)

Audience votes “yes” or “no”

11:30-11:50 YES	Bertrand Arnulf (Paris)
11:50-11:55 *Discussi*on	
11:55-12:15 NO	Nelson Leung (Rochester)
12:15-12:20 *Discussion*	

Audience votes “yes” or “no”

12:20-12:40 Round up of meeting

MEETING CLOSURE